Health Journal Online

Category: Diseases & Conditions

  • What Type of Cancer Was He Diagnosed With and Is He Still Sick?

    What Type of Cancer Was He Diagnosed With and Is He Still Sick?

    James Van Der Beek’s unexpected cameo during the Dawson’s Creek reunion concert has fans once again asking tough questions: what type of cancer is the actor battling, and is he still fighting the disease?

    The 48-year-old star, forever remembered as Dawson Leery in the hit ’90s teen drama, first revealed in 2024 that he was facing a serious health battle.

    Though he couldn’t join the live event in New York, his virtual appearance reignited speculation and worry among fans, many of whom took to social media to express both concern and support.

    What Does James Van Der Beek Have?

    In an interview with People in November 2024, James Van Der Beek confirmed that he is battling Stage 3 colorectal cancer.

    ‘I have colorectal cancer. I’ve been privately dealing with this diagnosis and have been taking steps to resolve it, with the support of my incredible family,’ the actor said.

    This form of cancer affects the colon or rectum and is often detected during routine screenings such as colonoscopies. According to Mayo Clinic, symptoms can include persistent changes in bowel habits, abdominal discomfort, and weight loss without trying.

    Colorectal cancer is one of the most common cancers diagnosed worldwide, and early detection is considered key in improving survival rates. Van Der Beek’s openness about his illness has drawn attention to the importance of awareness, especially among younger adults who might overlook potential symptoms.

    James Van Der Beek’s Illness Timeline

    The actor first went public with his diagnosis in 2024, stating that he was undergoing treatment while continuing to focus on his family life. Van Der Beek and his wife, Kimberly, share six children, and he has often credited them as his motivation during his health struggles.

    In September 2025, Van Der Beek was due to appear at a one-night-only live reading of the Dawson’s Creek pilot script at the Richard Rodgers Theatre in New York. The event was organised as a reunion for fans and a fundraiser for the charity F Cancer. Just days before the reunion, Van Der Beek announced that he would not be attending in person after suffering from separate stomach viruses on top of his cancer battle.

    Although unable to take the stage, he surprised fans with a pre-recorded video appearance. In the clip, he thanked the audience, cast, and organisers, introducing Lin-Manuel Miranda as his understudy for the evening.

    @goss.ie #JamesVanDerBeek made an unexpected virtual appearance during the #DawsonsCreek reunion charity event on Monday night, after previously withdrawing due to illness. The star-studded charity event featured a live reading of the show’s pilot episode and brought together beloved Dawson’s Creek cast members including Michelle Williams, Katie Holmes, Joshua Jackson, Mary Beth Peil, John Wesley Shipp, Mary-Margaret Humes, Nina Repeta, Kerr Smith, Meredith Monroe, and Busy Philipps ❤️ Directed by Dawson’s Creek alum Jason Moore, the event supported F Cancer and also honored Van Der Beek, who was diagnosed with stage 3 colorectal cancer last year. 🎥 @backtoyoubobpod #dawsonscreekreunion ♬ original sound – Goss.ie


    Is James Van Der Beek Still Sick?

    The question ‘is James Van Der Beek sick?’ has become a trending search as fans follow his health updates. His absence from the reunion highlighted that he is still managing illness alongside treatment. While the actor has not disclosed specific details of his current medical regimen, his comments and public appearances confirm that his fight with cancer is ongoing.

    Support from his wife Kimberly and their children has been central to his journey. The family have shared glimpses of their life on social media, showing both the challenges and moments of hope as he continues treatment.

    Dawson’s Creek Reunion and Public Support

    The Dawson’s Creek reunion drew significant attention not only for nostalgia but also for its charitable cause. The event raised funds for F Cancer, an organisation dedicated to cancer education and early detection.

    Fans responded with strong messages of support for Van Der Beek after his video message was played at the theatre.

    Lin-Manuel Miranda’s appearance as Dawson Leery was also widely discussed, but it was Van Der Beek’s heartfelt words that left a lasting impression. Many fans took to social media to express admiration for his strength and resilience.

    Originally published on IBTimes UK



    Source link

  • First Successful Gene Therapy for Huntington’s Disease Slows Disease Progression by 75%

    First Successful Gene Therapy for Huntington’s Disease Slows Disease Progression by 75%

    An experimental gene therapy developed by uniQure has, for the first time, shown a dramatic slowing of Huntington’s disease progression in human patients, offering hope for a condition long considered incurable.

    How the Trial Worked

    The therapy, called AMT-130, was administered via a one-time neurosurgical procedure lasting 12 to 20 hours using a modified viral vector to deliver corrective DNA to regions of the brain affected by the disease. Patients treated with a high dose saw their disease progress 75% more slowly over a 36-month period compared to matched external controls. Secondary outcomes showed a 60% slower decline in functional abilities. The treatment was generally well-tolerated, with no major new safety concerns reported.

    Sarah Tabrizi, director of UCL’s Huntington’s Disease Centre, said these findings mark “We now have a treatment for one of the world’s more terrible diseases. This is absolutely huge. I’m really overjoyed.” uniQure now plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration in early 2026.

    Regulatory Advances & Future Steps

    Earlier in 2025, the FDA granted AMT-130 Breakthrough Therapy designation, which may expedite review and regulatory pathways. In a regulatory update, uniQure disclosed that it is aligning key analytic and manufacturing plans with FDA guidance ahead of the BLA submission.

    The company intends to use external control data sets, like ENROLL-HD, for primary comparisons in its statistical analysis plan.

    Why This Breakthrough Is So Significant

    • Disease-modifying therapy: Until now, Huntington’s treatments have only addressed symptoms; AMT-130 indicates the possibility of altering disease trajectory.
    • One-time administration: Because it is delivered via a single surgical procedure, its benefits—if durable—could last years without repeated dosing.
    • High unmet need: In the U.S., about 41,000 people live with Huntington’s and over 200,000 carry risk alleles.
    • Scientific validation: The magnitude of effect in this trial is among the most convincing in neurodegenerative disease research to date.

    How AMT-130 Compares to Other Gene Therapies

    AMT-130’s approach—one-time neurosurgical delivery of a vector designed to suppress the mutant huntingtin protein—is somewhat unique among genetic therapies, in both delivery method and disease target.

    Here are some points of comparison:

    Therapy Mode of Delivery / Regimen Indication / Age Group Key Strengths Known Limitations / Risks
    AMT-130 (uniQure) Single stereotactic brain surgery (direct striatal infusion) Early-manifest Huntington’s disease Promising stabilization of function, one-time treatment, demonstrable biomarker improvements Surgical risks, inflammatory complications, durable long-term efficacy unknown
    Zolgensma (Onasemnogene abeparvovec-AVXS-101) Single intravenous or intrathecal in some trials Spinal Muscular Atrophy (infants and older children) Has shown dramatic improvements in survival, motor function; among best-known successful gene therapies Very high cost, immune reactions, limited age window, administration logistics
    Nusinersen (Spinraza) Repeated intrathecal injections (ongoing) SMA across age groups Reduces disease burden, extends life, widely used; well-understood safety profile Requires regular dosing, invasiveness, burdens on patients/caregivers, cost

    Cautions and Limitations

    • Not a cure: While the slowing is impressive, it does not reverse the disease or fully stop its course.
    • Surgery risk and cost: The invasive nature and complexity of delivery limit its applicability, especially in less capable surgical settings.
    • Long-term durability unknown: Whether the effect holds beyond three years remains to be seen.
    • Regulatory and access hurdles: Approval does not guarantee access, and pricing, reimbursement, and manufacturing scale remain major challenges.

    Source link

  • CDC Report Shows More Children Are Either Dying or Becoming Severely Ill With Flu Amid Declining Vaccination Rates

    CDC Report Shows More Children Are Either Dying or Becoming Severely Ill With Flu Amid Declining Vaccination Rates

    The Centers for Disease Control and Prevention (CDC) released a report showing that more and more children are either dying or becoming severely ill with the flu amid declining vaccination rates in the United States.

    Now, cases of pediatric acute necrotizing encephalopathy (ANE) are on the rise, with 109 children being diagnosed during the 2024-25 flu season. This is a rare inflammatory brain disease caused by the illness.

    Rise in Flu-Related Deaths Among Kids

    A new report also showed that 84% of kids who have influenza-associated encephalopathy whose vaccination status was known were not vaccinated. This comes as the country recorded 280 pediatric flu deaths last year, which is the deadliest since the 2009-10 H1N1 pandemic.

    A pediatric infectious disease physician at Vanderbilt University Medical Center in Nashville, Dr. Buddy Creech, said that they do not always know how to predict which children are going to get the most severe forms of flu. This is why they recommend the vaccine for everyone, according to NBC News.

    ANE is considered a rare disease, as there are only a handful of cases recorded every year, and it has never been formally tracked. However, this year, doctors noted an increase in kids affected by the brain inflammation after suffering from the flu.

    A pediatric neurologist at Boston Children’s Hospital, Dr. Molly Wilson-Murphy, said that they are not yet sure if there really is an increase in real numbers. However, being on the ground as a physician, she was struck that it certainly is.

    The National Foundation for Infectious Diseases also underscored the crucial role that annual flu vaccinations play in preventing serious illness, particularly among children. The CDC recommends the shots for everyone aged six months and older yearly, KSTE reported.

    A Decline in Vaccination Rates

    Despite the decline in vaccination rates, the CDC continues to advocate for flu shots, saying these are the most effective way to protect kids from severe flu-related complications, as well as death.

    The situation comes after the Advisory Committee on Immunization Practices (ACIP) recently voted to change recommendations for the COVID-19 vaccine. These recommendations must still be approved by the CDC director in order to become official guidance.

    Advice on the COVID-19 vaccine differs from the flu shots, as the CDC said parents of healthy children aged six months to 17 years should talk about the benefits with a health care provider. The CDC broadly recommends the vaccine for moderately or severely immunocompromised kids, as per CBS News.



    Originally published on parentherald.com

    © {{Year}} ParentHerald.com All rights reserved. Do not reproduce without permission.

    Source link

  • Where To Get Huntington’s Disease Treatment? Hope Flows As Doctors Claim First Patient Cured From Neuro Illness

    Where To Get Huntington’s Disease Treatment? Hope Flows As Doctors Claim First Patient Cured From Neuro Illness

    In a groundbreaking development, researchers in the UK have reported the first-ever successful treatment for Huntington’s disease, a hereditary neurodegenerative disorder previously deemed incurable. The experimental gene therapy, known as AMT-130, slowed disease progression by 75% over three years, offering renewed hope to patients and families affected by the condition.

    What Is Huntington’s Disease?

    Huntington’s disease is a progressive neurological disorder caused by a mutation in the HTT gene, leading to the production of a toxic protein that damages brain cells. Symptoms typically manifest in mid-adulthood and include motor dysfunction, cognitive decline, and psychiatric disturbances. The disease is fatal, with patients often succumbing within 15–20 years of symptom onset.

    The Breakthrough Treatment

    Led by Professor Sarah Tabrizi at University College London (UCL), the pioneering clinical trial utilised an innovative gene therapy approach. The treatment involves a one-time surgical procedure lasting up to 20 hours, during which a specially engineered, harmless virus is infused directly into the brain. This virus carries a DNA strand designed to deactivate the mutant huntingtin protein responsible for the disease.

    The results have been nothing short of remarkable. According to a press release from UCL, patients who underwent the treatment experienced a 75% reduction in the expected progression of the disease over a three-year period. Instead of the expected rapid decline, these patients maintained neurological function, effectively gaining years of quality life.

    Expert Insights

    Professor Tabrizi expressed her astonishment at the results, stating, ‘We never in our wildest dreams would have expected a 75% slowing of clinical progression.’ She emphasised that this breakthrough could pave the way for earlier interventions, potentially preventing the onset of symptoms altogether.

    Where to Access Huntington’s Disease Treatment in the UK

    For individuals seeking treatment or support for Huntington’s disease, the UK offers several renowned centres specialising in diagnosis, care, and research:

    • University College London (UCL) Institute of Neurology: A leading research and clinical centre focusing on Huntington’s disease, offering multidisciplinary care and conducting pioneering clinical trials.
    • Cardiff University Huntington’s Disease Centre: A prominent centre dedicated to research and coordination of Huntington’s disease studies across South Wales.
    • Royal Hospital for Neuro-disability: Specialises in providing care and support for patients with complex needs due to Huntington’s disease.
    • Guy’s and St Thomas’ NHS Foundation Trust: Offers follow-up services for individuals diagnosed with Huntington’s disease, including participation in clinical trials.

    These institutions are at the forefront of Huntington’s disease care and research, providing essential services to patients and families affected by the condition.

    Global Implications

    Approximately 6,000 to 10,000 individuals in the UK are affected by Huntington’s disease, with many more at risk due to family history. The success of this gene therapy trial has the potential to revolutionise treatment approaches globally.

    Biotechnology company UniQure plans to seek approval for the therapy in the United States, signalling a new era in the fight against this devastating disorder.

    Looking Ahead

    While gene therapy presents a promising avenue for treatment, the procedure remains complex and expensive. As the medical community continues to assess its long-term efficacy and accessibility, this breakthrough stands as a powerful testament to scientific innovation and its potential to transform lives.

    Originally published on IBTimes UK

    Source link

  • How MOA Reimagined Mental Health Support at the Traverse Academy

    How MOA Reimagined Mental Health Support at the Traverse Academy

    In a time where children face not just academic pressures but increasing mental health crises, from anxiety and depression to the unimaginable trauma of school shootings and suicide loss, architecture would rarely be the first thought in the conversation. But at MOA Architecture, it is more than just a structure. It is an intervention, backed by careful design.

    The Denver-based firm, known for its thoughtful, human-centered design, recently completed a pilot project with Cherry Creek School District: Traverse Academy, a day-treatment facility owned and operated by a public school district. The project wasn’t just another commission. For MOA, it was a mission. And for President and Director of Healthcare Design Katie Vander Putten, it was deeply personal.

    “After COVID, suicide became one of the leading causes of death among students in some districts,” she says. “And across Colorado, the number of facilities for youth mental health care has dwindled. We knew something had to change,” Vander Putten says.

    Traverse Academy is a therapeutic school environment for students in grades 4–12 experiencing acute mental health challenges, from severe trauma to transitional anxiety. It merges clinical treatment with education in a safe, supportive environment designed not just for learning, but for healing.

    Split into three tiers: Severe, Moderate, and Transitional, the building was designed with intention at every step. The severe wing supports students recently discharged from clinical facilities. The moderate level reintroduces academic routines alongside therapy. Transitional spaces help students reintegrate into their original school environments while still receiving ongoing support.

    What makes the academy so revolutionary isn’t just its purpose; it’s the way it was designed.

    MOA didn’t start with a traditional floor plan. Instead, they spoke directly to students and imagined a ‘day in the life’ walking through the doors for the first time, possibly after a traumatic experience.

    “Children wouldn’t want to walk into a cold waiting room with fluorescent lights,” Vander Putten explains. “Imagine them walking into a space that feels like a coffee shop, greeted with warmth. You can go outside, take a walk, or have an art class. It’s about regaining control of their surroundings, choices, and future.”

    The design team deeply considered two kinds of trauma responses in children: internalizers, who may withdraw and self-harm, and externalizers, who act out physically. To accommodate both, spaces include everything from calming corners with natural light to punching bags, climbing walls, and color-coded wings that visually signal progression and achievement.

    Every material, color, and layout was researched through a trauma-informed lens. “There’s data behind everything,” says Vander Putten, whose background is in healthcare and trauma-responsive environments. “Even down to the wood tones on the walls. If it doesn’t reflect what you’d find in nature, it actually agitates the nervous system.”

    One of the most powerful aspects of the project is its reimagination of how these spaces should be. “We wanted students to walk in and think: They built this for me. They care about me,” Vander Putten says. “When kids feel respected by their space, they’re less likely to act out. They feel proud, and that matters.”

    The facility also allows students to move fluidly between different learning and therapy modalities. Some may be there for a few weeks, others for a few months.

    Since the academy opened, MOA has been speaking nationally about the project: at education conferences, AIA events, and within architecture circles. But now, the team wants to go further: they want to help other schools adapt these principles. “We know not every district can build a facility from scratch,” Vander Putten says. “But with thoughtful adaptive reuse, you can create refocus rooms, therapy zones, and transitional spaces within existing schools. You can make meaningful change without starting from the ground up.”

    Despite the project’s success, funding models remain a barrier. Medicare and Medicaid restrictions complicate public-private partnerships, and many schools struggle to secure investment. Cherry Creek’s effort required the district to hire its own clinicians, develop its own malpractice coverage, and operate independently of traditional hospital systems. Still, the success of Traverse Academy is proving what’s possible and urgently needed.

    As Vander Putten concludes, “We want to honor them by making sure this doesn’t stay a one-off. If we can help one more district, in our own way, help save one more child, that’s worth everything.”

    Source link

  • Internet Reacts To Trump’s Unproven Claim Linking Tylenol Use During Pregnancy To Autism

    Internet Reacts To Trump’s Unproven Claim Linking Tylenol Use During Pregnancy To Autism

    US President Donald Trump, joined by Robert F. Kennedy Jr., recently claimed that the use of Tylenol (acetaminophen) during pregnancy is linked to a rise in autism, urging women to avoid it unless absolutely necessary. He also suggested re-evaluating vaccine schedules in children. Medical experts and pregnancy health authorities immediately criticised the statements as lacking credible scientific support.

    Online, reactions have been intense and varied. On X/Twitter, many users expressed frustration and fear, saying the claims could cause undue worry among pregnant women. Memes have spread too — some exaggerated the scenario, others sarcastically comparing Tylenol to ‘superpowers’ lost if avoiding it. There are also posts sharing personal stories: parents debating whether their own use of painkillers might have played a role, even though they acknowledge they weren’t doctors. Meanwhile, groups such as the National Autistic Society condemned the claim, calling it ‘anti-science’ and warning against the spread of misinformation.










    Medical experts emphasise that decades of research, including large-scale Swedish and US studies, have found no causal link between acetaminophen use in pregnancy and autism. Makers of Tylenol, Kenvue, issued statements opposing Trump’s claim, citing the drug’s record of safety. Health regulators in the UK and elsewhere also reaffirmed that Tylenol remains among the safest options for treating pain and fever in pregnant women, when used correctly.

    Originally published on IBTimes UK



    Source link

  • Trump to Discuss New Autism Findings After Hinting At Major Discovery During Kirk Memorial

    Trump to Discuss New Autism Findings After Hinting At Major Discovery During Kirk Memorial

    At Charlie Kirk’s memorial, President Donald Trump veered off-script to reveal his administration had uncovered new findings on autism. He hinted that an upcoming public health briefing will examine possible links between acetaminophen, widely sold as Tylenol, and autism spectrum disorder (ASD).

    Reports suggest Trump’s remarks may also extend to cautioning pregnant women about routine acetaminophen use, signalling a controversial shift in health guidance that could spark nationwide debate.

    Trump’s planned comments are expected to highlight leucovorin, a medication traditionally used for anaemia and certain cancer treatments, as a potential therapy aimed at improving communication skills in children with autism.

    The briefing will be attended by Health Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, and CMS Administrator Mehmet Oz.

    Background: Tylenol and Autism Research

    The announcement arrives amid rising public concern about environmental and pharmaceutical factors contributing to autism. Tylenol, or acetaminophen, is widely used during pregnancy to reduce fever and manage pain.

    Some studies have suggested a possible association between prenatal acetaminophen exposure and developmental disorders, though findings remain inconclusive.

    Autism diagnoses in the United States have increased over the last two decades. Data from the Centers for Disease Control and Prevention indicate that 1 in 31 American 8-year-olds are now diagnosed with autism, compared with 1 in 150 in 2000.

    The administration cited environmental toxins as a possible contributor, while many experts emphasise that improved diagnosis and greater awareness are likely key drivers of the rising numbers.

    Leucovorin Highlighted as Potential Autism Treatment

    In addition to cautioning against Tylenol, the White House is expected to focus on leucovorin as a potential treatment. Early research suggests that the drug may improve communication and cognitive function in some children with autism.

    Leucovorin is a derivative of folic acid and has traditionally been used to treat certain forms of anaemia and to counteract side effects from chemotherapy.

    Experts emphasise that the research on leucovorin remains preliminary. Clinical trials are ongoing, and scientists stress that results must be interpreted cautiously before the drug can be widely recommended as a standard treatment for autism.

    Medical Community Raises Concerns

    The proposed guidance has prompted concern among health professionals. Many doctors argue that current evidence does not support a definitive link between acetaminophen use in pregnancy and autism.

    The American College of Obstetricians and Gynecologists and the American Academy of Pediatrics continue to consider acetaminophen safe when taken as directed.

    Kenvue, the manufacturer of Tylenol, released a statement asserting that there is no conclusive evidence linking acetaminophen to autism.

    Experts warn that public confusion over these claims could lead to unnecessary avoidance of the medication and potential health risks, particularly when fever management is critical during pregnancy.

    Implications for Public Health

    Trump’s announcement represents a notable shift in messaging around acetaminophen use during pregnancy. While the guidance is not legally binding, it could influence public behaviour, prenatal care practices, and media coverage.

    Healthcare providers are encouraged to discuss risks and benefits with their patients and to stay informed about ongoing research.

    Further studies on both acetaminophen exposure and potential autism treatments, including leucovorin, are expected to provide clearer guidance in the coming years. Regulatory agencies, including the FDA, are monitoring the situation closely to evaluate any policy adjustments.

    Originally published on IBTimes UK

    Source link

  • Making Brain-Health Supplements Work Day to Day

    Making Brain-Health Supplements Work Day to Day

    The role of nutritional supplementation in supporting brain health has gained increasing attention in recent years, particularly as global populations age and the burden of neurodegenerative concerns rises. While the commercial availability of “nootropic” and brain-health supplements has expanded rapidly, their clinical efficacy depends less on ingestion and more on integration into sustained, evidence-based health practices.

    Understanding the Role of Brain-Health Supplements

    Cognitive performance and neuroprotection rely on complex interactions between neurotransmitters, vascular health, and cellular resilience. Science-backed nootropic supplements for brain health are typically formulated to provide nutrients and bioactive compounds that support these processes.
    Omega-3 fatty acids (DHA and EPA)

        are essential for neuronal membrane fluidity and synaptic signaling. Meta-analyses suggest that omega-3 supplementation may improve memory, learning, and executive function and help fight age-related cognitive decline

    1
    • B vitamins (e.g., folate, B6, B12) regulate homocysteine metabolism; elevated homocysteine is associated with cognitive impairment and dementia risk 3.
    • Adaptogens such as Rhodiola rosea and Panax ginseng may modulate stress response pathways via the hypothalamic–pituitary–adrenal axis, with preliminary evidence of improved mental fatigue and resilience 4.
    • Amino acids such as L-theanine appear to influence alpha brainwave activity and GABA/glutamate neurotransmission, contributing to enhanced attention and reduced stress 5.

    No supplement acts as a pharmacological “quick fix.” Their role is adjunctive, best positioned within multimodal interventions that include nutrition, physical activity, sleep regulation, and stress reduction.

    Creating Consistency in Supplement Use

    Clinical outcomes from supplementation are contingent upon regular intake over time, as nutrient effects accumulate systemically. Strategies to enhance adherence include:

    • Habit stacking, in which supplement administration is paired with an established daily behavior (e.g., morning hygiene or coffee preparation).
    • Behavioral prompts, such as phone alarms, digital reminders, or visible placement of supplements within daily environments.
    • Structured organization (e.g., pill organizers) to reduce cognitive load and ensure dose accuracy.

    Just like any other healthy lifestyle practice, consistent supplement use brings the best potential benefits.

    Synergistic Role of Lifestyle Factors

    Supplements function optimally when biological systems are primed through foundational health practices:

    • Nutrition: Diets rich in polyphenols, flavonoids, and unsaturated fatty acids—such as the Mediterranean diet—are associated with reduced risk of cognitive decline and Alzheimer’s disease 7.
    • Hydration: Mild dehydration impairs attention, executive function, and short-term memory, with rehydration reversing deficits 8.
    • Sleep: Adequate sleep is critical for synaptic homeostasis, memory consolidation, and clearance of neurotoxic metabolites via the glymphatic system 9.
    • Exercise: Regular aerobic activity upregulates brain-derived neurotrophic factor (BDNF), enhances neurogenesis in the hippocampus, and improves executive function 10.

    Personalizing Supplementation Strategies

    Supplement selection should align with the individual’s demographic, clinical background, and cognitive objectives:

    • Students and early-career professionals: supplementation may focus on attentional control and working memory.
    • High-stress populations: adaptogens and amino acids may mitigate stress-induced cognitive fatigue.
    • Older adults: neuroprotective compounds such as omega-3s, B vitamins, and polyphenols may support healthy aging.

    The heterogeneity of formulations underscores the importance of aligning supplementation with individual risk factors and evidence-based outcomes rather than generalized claims.

    Monitoring Efficacy and Adherence

    Unlike pharmacological agents, supplement outcomes are often subtle and gradual. Clinicians and individuals may benefit from:

    • Journaling or ecological momentary assessment (EMA) of mood, energy, and cognitive performance.
    • Standardized cognitive assessments, where feasible, to detect changes in working memory, attention, or executive function.
    • Self-monitoring tools (e.g., digital health apps, wearables) that capture sleep, stress, and focus patterns.

    Longitudinal self-reporting aids motivation while also generating real-world data on supplement efficacy.

    Addressing Common Barriers

    Supplement adherence disruptions commonly include travel, workload, or simple forgetfulness. Practical mitigation strategies involve portable pill containers, weekly dose batching, and prioritization of essential interventions during periods of high demand. Evidence from behavioral science indicates that environmental design—structuring cues and reducing barriers—improves long-term adherence 11.

    Conclusion

    Brain-health supplements may contribute to cognitive resilience, but their benefits are maximized only when integrated into a broader framework of healthy living. Sustained adherence, combined with nutrition, hydration, exercise, and sleep, provides the biological substrate for these compounds to act effectively.

    Ultimately, supplement use should be considered not as a discrete intervention, but as one element in a multidimensional approach to cognitive health across the lifespan.

    References

    1. Yurko-Mauro K, Alexander DD, Van Elswyk ME. Docosahexaenoic acid and adult memory: a systematic review and meta-analysis. PLoS One. 2015;10(3):e0120391. PubMed
    2. National Institutes of Health (NIH) Office of Dietary Supplements. Omega-3 Fatty Acids – Fact Sheet for Consumers. NIH ODS
    3. Mayo Clinic. Alzheimer’s disease: Can vitamins and supplements help? Mayo Clinic
    4. Cleveland Clinic. Rhodiola (Rhodiola rosea). Cleveland Clinic
    5. Hidese S, Ogawa S, Ota M, et al. Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients. 2019;11(10):2362. PubMed
    6. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26(3):155–159. PubMed
    7. Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med. 2015;175(7):1094–1103. PMC
    8. Masento NA, Golightly M, Field DT, Butler LT, van Reekum CM. Effects of hydration status on cognitive performance and mood. Br J Nutr. 2014;111(10):1841–1852. PMC
    9. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–377. NIH
    10. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017–3022. PMC
    11. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42. PubMed

    Source link

  • Dr. Robin Miller is On a Mission to Put Prevention Back into Individuals’ Hands

    Dr. Robin Miller is On a Mission to Put Prevention Back into Individuals’ Hands

    The last half-century has brought major leaps in medical technology. Sophisticated scans, cutting-edge tests, and an ever-expanding menu of supplements have transformed how illness is detected and treated. Yet, paradoxically, many argue that the ‘art’ of medicine, the attentive listening, the focus on whole-body wellness, has slipped into the shadows. For countless patients, technology now speaks louder than the human touch.

    Dr. Robin H. Miller, an integrative medicine physician and author, believes that this imbalance has come at a cost. “Our medical system is broken,” she says. “It was flawed before the pandemic and only grew worse after COVID. Too many patients have fallen through the cracks.” Her conclusion is simple, but urgent: individuals must become their own partners in health. Doctors and hospitals are critical when crises strike, but prevention and daily wellness rest in each person’s hands.

    It is this conviction that people themselves hold the power to stay well that drives Miller’s work today. And it is the reason she decided to do something unconventional: create a series of books that makes medicine accessible, relatable, and even enjoyable.

    Miller’s path to this mission began in the halls of a hospital, where she trained in preventative cardiology. Helping families break cycles of heart disease inspired her, but a move to Oregon and the realities of standard practice soon tempered that optimism. Ten-minute appointments, rushed conversations, and quick fixes left her questioning whether she was truly helping people.

    So she pivoted. Miller pursued an integrative medicine fellowship and launched Triune Integrative Medicine, a clinic centered on hour-long visits, deep listening, and wellness-focused care. The results spoke for themselves. “Most of the time, patients will tell you what’s wrong if you listen,” she explains. That philosophy not only improved outcomes but also rekindled her passion for medicine.

    Her work extended beyond the clinic. As host of NBC5’s Focus on Health, she reached thousands each week. She also developed a course, The Scientific Guide to Health and Happiness. And even turned to writing, first traditional guides, and later a creative series.

    Miller knew from experience that patients often tune out traditional medical advice. “Adults don’t always listen to their doctors. They listen to friends, family, or social media,” she says. To bridge that gap, she returned to a childhood classic: Dick and Jane.

    Her new series, ‘A Healthy Journey with Dick and Jane,’ translates complex health concepts into simple, illustrated stories. Using humor, bite-sized explanations, and even AI-generated visuals, the books invite readers to explore topics like heart health, gut health, brain function, and more, without the intimidation of jargon or the pressure of clinical authority.

    The series includes Mind Your Health, The Beat Goes On, Gut Instinct, Solid Ground, Skin Health, and Health 101: A Healthy Journey with Dick and Jane. The upcoming one will be on menopause, demystifying one of the most misunderstood stages of women’s health.

    By weaving evidence-based advice into the familiar rhythms of Dick and Jane storytelling, Miller lowers the barrier to entry. “Health isn’t complicated,” she insists. “But you have to do it. You have to be motivated, and sometimes that means making it fun.”

    The wellness industry is booming, but Miller sees danger in the noise. Every online search brings conflicting answers. Every company promises a miracle supplement or device. The overload leaves people confused, frustrated, and often paralyzed.

    Miller’s counterpoint is clarity. Her books focus on timeless basics, moving your body, eating a Mediterranean-style diet, prioritizing sleep, reducing stress, and cultivating community. No fad diets. No magic pills. Just sustainable habits that empower individuals to prevent disease before it starts.

    And importantly, her approach emphasizes individuality. “Everyone is unique. What works for one person may not work for another,” she says. “The goal is to give people options and help them discover their own path.”

    For Miller, the book series is not the final word, but the beginning of a movement. It is a way of changing the mindset from dependency on a faltering system to personal agency in health. She sees it as a model for how society at large can approach not just medicine, but any area where institutional trust is eroding.

    In a time when medicine often feels more mechanical than human, Miller’s message is refreshingly direct: “We already have the tools to heal, we just need to use them.”

    Source link

  • Photos Of Alison Hammond’s Dramatic Weight Loss: British TV Presenter Looks Unrecognisable

    Photos Of Alison Hammond’s Dramatic Weight Loss: British TV Presenter Looks Unrecognisable

    TV favourite Alison Hammond flaunted her shocking transformation after losing more than 13 stones in recent years.

    The ‘This Morning’ star looked extra confident and cheerful on the set of The Great British Bake Off, wearing a plain white T-shirt, a colourful skirt, and a denim jacket that highlighted her slimmer figure.

    Hammond, aged 50, weighed 28 stone at her heaviest. But after receiving a pre-diabetic diagnosis, the TV host decided to live a healthier lifestyle and managed to lose at least 13 stones.



    How Did She Lose the Weight?

    In a recent interview with Heat, Hammond gushed about how she managed to lower the scales.

    ‘I’ve got a personal trainer – she’s amazing, she trains me when I can train,’ she shared.

    ‘If I’m working, I don’t train, I’ll go for a walk. But when I’m at home, I’ll go and have a session with her in the morning, just an hour. It might be four days a week.’

    For her diet, the host said that she starts her day with a ginger shot to boost her immune system before consuming a Full English breakfast, complete with eggs, sausages and bacon.

    During the days when she is working, her usual lunch is Caribbean food like rice, chicken and peas. But if she is staying at home, she would bake herself some lasagne.

    Lighter and Happier

    A source also told the Daily Mirror that Hammond is ‘happier than ever.’ She also opted for natural weight loss and refused to undergo any drastic diet. Instead, she opted to work with a personal trainer and eat anything she likes ‘in moderation.’

    She previously tried weight intervention methods to lose the extra pounds when she had a gastric band fitted back in 2007, but she had it removed three years later after her body opted against it.

    According to the source, ‘She’s worked so hard since she first started in TV and work has always been her biggest priority after Aidan, but that’s changed now. She’s got a better balance. Her own needs and her love life are much more of a priority – and it shows.’

    Her new positive outlook comes with the revelation about her relationship with her 28-year-old boyfriend, David Putman, who reportedly has her feeling ‘on top of the world.’

    She also admitted in an interview with Romesh Ranganathan’s Parents Evening where she appeared with her son Aidan that he gives great relationship advice and is a major part of the success of her love life.

    The fans also noticed both the physical and non-physical transformations from Hammond’s latest pictures.

    One of her social media followers said, ‘Wow did not even recognise you Alison you look fantastic,’ whilst another said, ‘You look amazing and love watching you on TV, such a breath of fresh air.’

    Another fan also commented on Hammond’s lighter disposition, saying: ‘Love her so much she always brings a smile to my face. She also looks so happy and healthy and stunning lately.’

    Meanwhile, another one claimed that her new look is inspiring. ‘Such an inspirational weight loss journey. Hard work pays off, and you look incredible,’ the commenter said.

    Check out Hammond’s amazing weight transformation.

    Alison Hammon weight loss journey
    Facebook/Alison Hammond



    Alison Hammon weight loss journey



    Alison Hammon weight loss journey
    Facebook/Alison Hammond



    Alison Hammon weight loss journey



    Alison Hammon weight loss journey
    Facebook/Alison Hammond



    Alison Hammon weight loss journey



    Alison Hammon weight loss journey
    Facebook/Alison Hammond



    Alison Hammon weight loss journey



    Alison Hammon weight loss journey
    Facebook/Alison Hammond



    Alison Hammon weight loss journey



    Alison Hammon weight loss journey
    Facebook/Alison Hammond



    Alison Hammon weight loss journey



    Alison Hammon weight loss journey
    Facebook/Alison Hammond


    Originally published on IBTimes UK

    Source link